AUROPHARMA2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2019-10-012019-12-31in-bse-fin:OneOperatingExpenses02Member AUROPHARMA2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member AUROPHARMA2019-10-012019-12-31in-bse-fin:FourOperatingExpenses02Member AUROPHARMA2019-10-012019-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2019-10-012019-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2019-10-012019-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AUROPHARMA2019-10-012019-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AUROPHARMA 2019-04-01 2020-03-31 2020-01-30 INR Lakhs Third quarter Single segment Pharmaceutical Products 2019-10-01 2019-12-31 Unaudited Consolidated 58950000000.00 219900000.00 59169900000.00 20111500000.00 5531000000.00 7500000.00 7978000000.00 371100000.00 2501300000.00 13152200000.00 49652600000.00 9517300000.00 -129200000.00 9388100000.00 2179600000.00 149000000.00 2328600000.00 0.00 7059500000.00 0.00 0.00 0.00 -6400000.00 7053100000.00 1112200000.00 8165300000.00 7054500000.00 -1400000.00 8166700000.00 -1400000.00 585900000.00 1 12.04 12.04 0.00 0.00 12.04 12.04 1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.t n tttttttt n2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on Consolidated financial statements and Ind AS 28 on Investments in Associates and Joint ventures notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.t n tttttttt n3 The above conoslidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 6 February 2020. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2019. An unmodified report has been issued by them thereon.t n tttttttt n4 Effective 1 April 2019, the Group adopted Ind AS 116, on all lease contracts existing on 1 April 2019 using the modified retrospective method with Right-of-use assets recognized at an amount equal to the lease liabilities in the balance sheet. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs. 51,977 lakhs (includes reclassification of finance lease assets of Rs. 11,594 lakhs as at 31 March 2019) and lease liabilities of Rs. 47,535 lakhs (includes reclassification of finance lease obligations of Rs. 7,152 lakhs as at 31 March 2019). The adoption of the standard did not have any material impact to the financial results.t n tttttttt n5 Exceptional items for the current period/year represent acquisition related costs.t n tttttttt n6 The Group operates in only one segment viz., 'Pharmaceutical Products'.t n tttttttt n7During the quarter, the following entities have been incorporated: na) Aurobindo NV/SA, a wholly owned subsidiary of Agile Pharma B.V., w.e.f. 17 December 2019 nb) LONGXIANG PHARMA TAIZHOU CO., LTD, a Joint venture under Helix Healthcare B.V. w.e.f 28 October 2019.t n tttttttt n8 Aurobindo Pharma USA LLC a wholly owned subsidiary of Aurobindo Pharma USA Inc. was sold w.e.f.15 November 2019.t n tttttttt n9 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Group has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.t n tttttttt n10 The joint petition seeking sanction of the Hon’ble National Company Law Tribunal, Hyderabad Bench (NCLT) for the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited (all wholly owned subsidiary companies) with the Parent Company has been admitted and is scheduled for hearing on 28 February 2020. t n tttttttt n11 The Board has approved second interim dividend @175% i.e., Re.1.75(Rupee One and Seventy five paise only) per equity share of Re.1 (Rupee One only) for the year 2019-20.t n tttttttt n12 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to conform to the current period presentation. Single segment 2019-04-01 2019-12-31 Unaudited Consolidated 169400700000.00 536100000.00 169936800000.00 56870000000.00 15988700000.00 -540100000.00 23548500000.00 1279400000.00 7343000000.00 38449800000.00 142939300000.00 26997500000.00 -383800000.00 26613700000.00 6301600000.00 548300000.00 6849900000.00 0.00 19763800000.00 0.00 0.00 0.00 41400000.00 19805200000.00 1383700000.00 21188900000.00 19811400000.00 -6200000.00 21195100000.00 -6200000.00 585900000.00 1 33.81 33.81 0.00 0.00 33.81 33.81 Foreign Exchange Fluctation(gain)/Loss -89400000.00 Other Expenditure 13241600000.00 Foreign Exchange Fluctation(gain)/Loss 135100000.00 Other Expenditure 38314700000.00